Related Experiment Video
Updated: May 11, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Potent anticancer activity of cystine-based dipeptides and their interaction with serum albumins
Biswadip Banerji1, Sumit Kumar Pramanik, Uttam Pal
1Department of Chemistry, CSIR-Indian Institute of Chemical Biology, 4, Raja S,C, Mullick Road, Kolkata 700032, India. biswadip.banerji@gmail.com.
Background:
Cancer is a severe threat to the human society. In the scientific community worldwide cancer remains a big challenge as there are no remedies as of now. Cancer is quite complicated as it involves multiple signalling pathways and it may be caused by genetic disorders. Various natural products and synthetic molecules have been designed to prevent cell proliferation. Peptide-based anticancer drugs, however, are not explored properly. Though peptides have their inherent proteolytic instability, they could act as anticancer agents.
Results:
In this present communication a suitably protected cystine based dipeptide and its deprotected form have been synthesized. Potent anticancer activities were confirmed by MTT assay (a laboratory test and a standard colorimetric assay, which measures changes in colour, for measuring cellular proliferation and phase contrast images. The IC50 value, a measure of the effectiveness of a compound in inhibiting biological or biochemical function, of these compounds ranges in the sub-micromolar level. The binding interactions with serum albumins (HSA and BSA) were performed with all these molecules and all of them show very strong binding at sub-micromolar concentration.
Conclusions:
This study suggested that the cystine-based dipeptides were potential anticancer agents. These peptides also showed very good binding with major carrier proteins of blood, the serum albumins. We are currently working on determining the detailed mechanism of anticancer activity of these molecules.
Insights
New cystine-based dipeptides show potent anticancer activity, demonstrating strong binding to serum albumins. These findings highlight their potential as novel peptide-based anticancer drugs, warranting further investigation into their mechanisms.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Drug Discovery
Background:
- Cancer presents a significant global health challenge due to its complex signaling pathways and genetic origins.
- While various synthetic molecules target cancer, peptide-based therapeutics remain underexplored despite their potential.
- Peptides, though susceptible to degradation, offer promise as anticancer agents.
Purpose of the Study:
- To synthesize and evaluate novel cystine-based dipeptides for anticancer properties.
- To assess the binding affinity of these dipeptides with serum albumins.
- To establish a foundation for developing peptide-based anticancer drugs.
Main Methods:
- Synthesis of protected and deprotected cystine-based dipeptides.
- Anticancer activity assessment using MTT assays and phase contrast imaging.
- Evaluation of binding interactions with human serum albumin (HSA) and bovine serum albumin (BSA).
Main Results:
- Synthesized dipeptides exhibited potent anticancer activities with IC50 values in the sub-micromolar range.
- All synthesized compounds demonstrated strong binding interactions with serum albumins (HSA and BSA) at sub-micromolar concentrations.
- MTT assays and phase contrast images confirmed significant inhibition of cancer cell proliferation.
Conclusions:
- Cystine-based dipeptides represent promising candidates for anticancer drug development.
- The strong binding to serum albumins suggests favorable pharmacokinetic properties for these peptides.
- Further research is underway to elucidate the precise mechanisms underlying their anticancer effects.